{"id":"pirfenidone-capsules","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Gastrointestinal disturbances (nausea, dyspepsia, vomiting)"},{"rate":"10-15","effect":"Photosensitivity reaction"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Anorexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pirfenidone is an antifibrotic agent that suppresses the activity of transforming growth factor-beta (TGF-β) and other fibrogenic mediators, thereby reducing extracellular matrix deposition and fibroblast activation. It works through multiple pathways to inhibit the progression of pulmonary fibrosis by decreasing inflammatory cytokine production and fibroblast differentiation into myofibroblasts.","oneSentence":"Pirfenidone reduces fibroblast proliferation and collagen production by inhibiting multiple pro-fibrotic cytokines and growth factors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:27.789Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Idiopathic pulmonary fibrosis (IPF)"}]},"trialDetails":[{"nctId":"NCT07454291","phase":"PHASE1","title":"A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Endeavor Biomedicines, Inc.","startDate":"2026-03","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":57},{"nctId":"NCT07456800","phase":"PHASE1","title":"PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects","status":"COMPLETED","sponsor":"PureTech","startDate":"2021-07-12","conditions":"Pharmacokinetic Analysis","enrollment":116},{"nctId":"NCT07388680","phase":"PHASE2, PHASE3","title":"Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-02-28","conditions":"Radiation-induced Lung Injury, Immune-related Pneumonia","enrollment":298},{"nctId":"NCT06871904","phase":"PHASE1, PHASE2","title":"Fibrosis-Modulating Effects of Metformin and Pirfenidone in Oral Submucous Fibrosis","status":"COMPLETED","sponsor":"Ziauddin University","startDate":"2025-04-07","conditions":"Oral Submucous Fibrosis","enrollment":45},{"nctId":"NCT05195918","phase":"PHASE1","title":"Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hal Chapman","startDate":"2023-08-24","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":50},{"nctId":"NCT07325357","phase":"PHASE4","title":"Effect of Pirfenidone on TA Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-20","conditions":"Takayasu Arteritis","enrollment":92},{"nctId":"NCT07284602","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)","status":"NOT_YET_RECRUITING","sponsor":"PureTech","startDate":"2026-04","conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":1100},{"nctId":"NCT03177291","phase":"PHASE1","title":"Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-09-26","conditions":"Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer","enrollment":48},{"nctId":"NCT06070610","phase":"PHASE1","title":"A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-11-08","conditions":"Healthy","enrollment":14},{"nctId":"NCT05288179","phase":"PHASE3","title":"Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis","status":"RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2022-06-07","conditions":"Pneumoconiosis","enrollment":272},{"nctId":"NCT07229716","phase":"PHASE1","title":"Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-11","conditions":"Pulmonary Fibrosis","enrollment":20},{"nctId":"NCT06928272","phase":"PHASE3","title":"Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study","status":"RECRUITING","sponsor":"Douglas D. Fraser","startDate":"2025-09-10","conditions":"Long COVID","enrollment":348},{"nctId":"NCT07015398","phase":"PHASE1","title":"A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants","status":"COMPLETED","sponsor":"Trevi Therapeutics","startDate":"2025-06-30","conditions":"Healthy Participants","enrollment":132},{"nctId":"NCT05704166","phase":"PHASE2","title":"PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2023-03-16","conditions":"Acute Lung Injury, Prevention","enrollment":214},{"nctId":"NCT03902509","phase":"PHASE2","title":"A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.","status":"COMPLETED","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2019-05-24","conditions":"Radiation-induced Lung Injury","enrollment":126},{"nctId":"NCT06224790","phase":"PHASE4","title":"Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy","status":"COMPLETED","sponsor":"Sidrah Lodhi","startDate":"2024-03-10","conditions":"Diabetic Nephropathies, Type 2 Diabetes","enrollment":60},{"nctId":"NCT04461587","phase":"PHASE2","title":"Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Pulmonary Research of Abingdon, LLC","startDate":"2020-08-31","conditions":"Coal Workers' Pneumoconiosis (Complicated)","enrollment":50},{"nctId":"NCT03221257","phase":"PHASE2","title":"Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate","status":"COMPLETED","sponsor":"Michael Roth","startDate":"2017-11-28","conditions":"Scleroderma, Systemic, Interstitial Lung Disease","enrollment":51},{"nctId":"NCT03359863","phase":"PHASE2","title":"Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-03-07","conditions":"Restrictive Chronic Lung Allograft Dysfunction, Lung Transplant Rejection","enrollment":10},{"nctId":"NCT05826821","phase":"","title":"Biomarkers in HF: Circulating Biomarkers of Fibrosis and Cardiovascular Disease","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2017-03-02","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":107},{"nctId":"NCT05428150","phase":"PHASE1","title":"Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers","status":"COMPLETED","sponsor":"Excalibur Pharmaceuticals, Inc.","startDate":"2022-08-08","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":32},{"nctId":"NCT05531955","phase":"PHASE2","title":"Pirfenidone Treat Myocardial Fibrosis After Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-08-05","conditions":"Myocardial Fibrosis","enrollment":100},{"nctId":"NCT03473340","phase":"PHASE2","title":"Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)","status":"TERMINATED","sponsor":"University of Michigan","startDate":"2018-04-27","conditions":"Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction","enrollment":24},{"nctId":"NCT04258397","phase":"PHASE2","title":"Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease","status":"UNKNOWN","sponsor":"Veterans Medical Research Foundation","startDate":"2020-10-26","conditions":"Chronic Kidney Disease","enrollment":200},{"nctId":"NCT04939467","phase":"PHASE1","title":"Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Blade Therapeutics","startDate":"2021-10-15","conditions":"Drug Drug Interaction","enrollment":86},{"nctId":"NCT04126538","phase":"PHASE1","title":"Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics","status":"UNKNOWN","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2019-08-27","conditions":"Renal Insufficiency","enrollment":24},{"nctId":"NCT03725852","phase":"PHASE2","title":"A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2018-09-27","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":68},{"nctId":"NCT03099187","phase":"PHASE2","title":"A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-05-15","conditions":"Lung Diseases, Interstitial","enrollment":253},{"nctId":"NCT04631354","phase":"PHASE1","title":"Study in Healthy Adults to Quantify Lung Deposition and Distribution of Radio-labelled S-770108 Inhalation Powder Formulation Delivered by a Novel Inhaler Device","status":"COMPLETED","sponsor":"Shionogi","startDate":"2020-11-09","conditions":"Healthy Volunteer","enrollment":12},{"nctId":"NCT04675619","phase":"PHASE2","title":"Evaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity Pneumonitis","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2019-12-01","conditions":"Hypersensitivity Pneumonitis","enrollment":40},{"nctId":"NCT03208933","phase":"PHASE3","title":"Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-23","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":60},{"nctId":"NCT03092102","phase":"PHASE1","title":"The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2017-05-20","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":136},{"nctId":"NCT02932566","phase":"PHASE2","title":"The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2017-03-02","conditions":"Cardiac Failure","enrollment":129},{"nctId":"NCT03981094","phase":"PHASE1","title":"A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-05-10","conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":22},{"nctId":"NCT02262299","phase":"PHASE2, PHASE3","title":"European Trial of Pirfenidone in BOS, A European Multi-center Study","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2015-05","conditions":"Disorder Related to Lung Transplantation, CLAD, Bronchiolitis Obliterans","enrollment":90},{"nctId":"NCT04193592","phase":"PHASE2","title":"Efficacy and Safety of Pirfenidone Treatment in HPS-ILD","status":"UNKNOWN","sponsor":"Jesse Roman","startDate":"2019-12-01","conditions":"Hermansky Pudlak Syndrome, Interstitial Lung Disease","enrollment":50},{"nctId":"NCT01872689","phase":"PHASE2","title":"A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-10-13","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":505},{"nctId":"NCT00076102","phase":"PHASE2","title":"Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-07-21","conditions":"Neurofibromatosis 1, Neurofibroma, Plexiform","enrollment":36},{"nctId":"NCT03068234","phase":"PHASE2, PHASE3","title":"Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-05","conditions":"Systemic Sclerosis","enrollment":72},{"nctId":"NCT02622477","phase":"","title":"Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-06","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":12},{"nctId":"NCT02525484","phase":"PHASE1","title":"A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08","conditions":"Healthy Volunteer","enrollment":44},{"nctId":"NCT01933334","phase":"PHASE2","title":"Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2013-10","conditions":"Systemic Sclerosis","enrollment":63},{"nctId":"NCT02161952","phase":"PHASE2","title":"Pirfenidone, an Antifibrotic and Antiinflammatory Drug","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2005-05","conditions":"Fibrosis, Hepatitis C Chronic","enrollment":150},{"nctId":"NCT00754780","phase":"PHASE2","title":"Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2000-09","conditions":"Neurofibromatosis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["F647"],"phase":"marketed","status":"active","brandName":"Pirfenidone Capsules","genericName":"Pirfenidone Capsules","companyName":"Shanghai Zhongshan Hospital","companyId":"shanghai-zhongshan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pirfenidone reduces fibroblast proliferation and collagen production by inhibiting multiple pro-fibrotic cytokines and growth factors. Used for Idiopathic pulmonary fibrosis (IPF).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}